| abstract |
The present invention relates to a triterpene glycoside saponin-derived azbunt, a synthetic method thereof, an intermediate therefor and a use thereof. QS-7 is a potent immuno-adjuvant that is significantly less toxic than the avant-related saponin QS-21, which is currently advantageously used in anti-cancer and anti-viral vaccines. Clinical development of QS-7 has been hampered by tedious isolation and purification protocols. A novel semisynthetic method of synthesizing QS-7, QS-21 and related analogs using hydrolyzed prosapogenin mixtures has been provided to provide access to QS-7 and QS-21 analogs for preclinical and clinical evaluation . |